Glyxambi 25 mg/1
empagliflozin and linagliptin · TABLET, FILM COATED · Boehringer Ingelheim Pharmaceuticals, Inc.
Glyxambi is a tablet, film coated containing empagliflozin and linagliptin at 25 mg/1, taken oral. Manufactured by Boehringer Ingelheim Pharmaceuticals, Inc..
Key Facts
- Brand Name
- Glyxambi
- Generic Name
- empagliflozin and linagliptin
- NDC Code (Product)
0597-0164- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Strength
- 25 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA206073
- Drug Class
- Sodium-Glucose Cotransporter 2 Inhibitor [EPC]; Dipeptidyl Peptidase 4 Inhibitor [EPC]
- Marketing Start
- 01/30/2015
Recall History
No Recall HistoryFrequently Asked Questions
What is Glyxambi used for?
Glyxambi contains empagliflozin and linagliptin. It is a tablet, film coated taken oral. Consult your doctor for specific uses.
Is Glyxambi a controlled substance?
Glyxambi is not classified as a controlled substance by the DEA.
What is the generic name for Glyxambi?
The generic name for Glyxambi is empagliflozin and linagliptin. There are no other listed brand versions of empagliflozin and linagliptin.
What is the NDC code for Glyxambi 25 mg/1?
The NDC (National Drug Code) for Glyxambi 25 mg/1 is 0597-0164, listed by Boehringer Ingelheim Pharmaceuticals, Inc..
Other Glyxambi Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)